

Development Programs - Hematology

DRUG	INDICATION	PHASE 1	PHASE 2	PHASE 3
Tislelizumab (anti-PD-1)	R/R cHL	[Red bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	R/R mature T- and NK-cell neoplasms	[Dark blue bar spanning PHASE 1 and PHASE 2]		
	R/R cHL	[Dark blue bar spanning PHASE 1 and PHASE 2]		
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK inhibitor)	B-cell lymphoid malignancies	[Purple bar spanning PHASE 1 and PHASE 2]		
BGB-11417 (Bcl-2 inhibitor) monotherapy	Mature B-cell malignancies	[Dark blue bar spanning PHASE 1 and PHASE 2]		
ME-401 (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*	CLL/SLL, and B-cell NHL	[Purple bar spanning PHASE 1 and PHASE 2]		
Zanubrutinib	R/R CLL/SLL	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	1L and R/R WM	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	R/R CLL/SLL	[Red bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	R/R MZL	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	B-cell lymphoid malignancies	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	Previously treated B-cell lymphoid malignancies	[Light blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	B-cell lymphoid malignancies	[Pink bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	B-cell lymphoid malignancies	[Red bar spanning PHASE 1, PHASE 2, and PHASE 3]		
Zanubrutinib + Lenalidomide +/- Rituximab	R/R DLBCL	[Red bar spanning PHASE 1, PHASE 2, and PHASE 3]		
Zanubrutinib + Obinutuzumab	R/R FL	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
	B-cell lymphoid malignancies	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
Zanubrutinib + Rituximab	1L MCL	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
Zanubrutinib + Tislelizumab	B-cell lymphoid malignancies	[Light blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		
Zanubrutinib +/- Venetoclax†	1L CLL/SLL	[Dark blue bar spanning PHASE 1, PHASE 2, and PHASE 3]		

■ Australia
 ■ Australia, China
 ■ China
 ■ Japan
 ■ Switzerland, United States
 ■ United States
 ■ Worldwide